$9.6bn P&ID fraud: Trinity Biotech’s MD escaped arrest – EFCC witness

A prosecution witness in the trial of $9.6billion Process and Industrial Development Limited, P&ID, fraud, Umar Babangida, on Thursday, told a Federal High Court sitting in Abuja that, efforts to bring the managing director of Trinity Biotech Nigeria Limited, Patrick Nash (a.k.a Gerald Nash) to trial, failed as he had fled the country before he could be arrested.

Trial judge in the matter is Justice D. Okorowo.

Testufying at the resumed hearing in the matter, Babangida said: “My team visited the office of Trinity Biotech Nigeria Limited, located on the 1st floor, Oyo State House, Ralph Shodende Street, Abuja where efforts were made to trace the Managing Director, whose name is Patrick Nash, also known as Gerald Nash, an Irish, but we were informed by the company`s directors, Ibrahim Millar and Uzor Eneli that he has long left the country.”

He also disclosed to the defence counsel, Michael Ajara, under cross examination that he headed the team that investigated the matter, that the investigation was prompted by a petition from the office of the Attorney General and Minister of Justice, owing to a judgment against the Federal Republic of Nigeria to the tune of $9.6billion in favor of P&ID company.

READ ALSO: Enugu: SEG congratulates Gov Mbah on victory at tribunal

“My team and I interacted with the Federal Ministry of Petroleum to aid our investigation.

“We also relied on responses from the Corporate Affairs Commission, CAC, where requests were made on the name of the company, names and addresses of shareholders, changes and information available with them which they provided with proof of documents.

“We further got a written reply from the Special Control Unit Against Money Laundering, SCUML to aid the investigation,” he added.

According to him, the team invited and interrogated the two directors of Trinity Biotech Ltd: Millar and Eneli whose statements were taken voluntarily.

Meanwhile, Justice Okorowo adjourned the matter till November 20 and 21, 2023, for continuation of hearing.

Leave a Reply

Your email address will not be published. Required fields are marked *